DOCSLIB.ORG

Investigating Cell Type Specific Mechanisms Contributing to Acute Oral Toxicity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Prieto et al.: Investigating cell type specific mechanisms contributing to acute oral toxicity Supplementary Data1 Tab. S1: Overview of collected information on specific target organ/system and general cytotoxicity for chemicals correctly assigned to the CLP acute oral toxicity category by the 3T3 NRU cytotoxicity assay General Nervous Cardiovascular GI Chemical Liver Lung Blood Kidney cytotoxicity system system system (±)-Propranolol hydrochloride x ax (4-ammonio-m-tolyl)ethyl(2- x x hydroxyethyl)ammonium sulphate 1,2,4-Trichlorobenzene x x 1,2-Dichlorobenzene x x 2,4,6- x x Tris(dimethylaminomethyl)phenol 2,4-Dichlorophenoxyacetic acid x x x 5,5-Diphenylhydantoin x x 5-Fluorouracil x x x x Acetophenone x Acetylsalicylic acid x x x x x x Acrolein x x Acrylamide x x x Ammonium chloride x ax ax Atropine sulfate monohydrate x x Benzaldehyde x x Cadmium (III) chloride x x x x x Caffeine x x x Chloroform x x ax x x x x Chloroquine bis(phosphate) x x Chlorpromazine x x x Codeine x x x x Colchicine x x x x Copper sulphate x x x Cupric sulfate pentahydrate x x Cyclosporin A x x x x Diazepam x Diphenhydramine hydrochloride x x Disopyramide x x Ethyl chloroacetate x x Ferrous sulphate x x x Glufosinate-ammonium x Glutethimide x ax x Hexachlorophene x x Lithium Carbonate x x x Lithium sulphate x x x Malathion x x Maleic acid x x Meprobamate x x Orphenadrine hydrochloride x x x x p-Benzoquinone x x x Phenol x x x x x Procainamide hydrochloride x x x Quinidine sulfate dehydrate x x x Resorcinol x x Rifampicin x x doi:10.14573/altex.1805181s2 ALTEX ##(#), SUPPLEMENTARY DATA 1 General Nervous Cardiovascular GI Chemical Liver Lung Blood Kidney cytotoxicity system system system Sodium Cyanate x x sodium oxalate x x x Sodium valproate x bx x x Thioridazine hydrochloride x x Valproic acid x x x x x GI: Gastrointestinal; CLP: Classification, labelling and packaging; NRU: Neutral Red Uptake; a Indirect effect: b chronic effect Tab. S2: Overview of collected information on specific target organ/system and general cytotoxicity for chemicals with CLP acute oral toxicity category under-predicted 3T3 NRU cytotoxicity assay General Nervous Cardiovascular GI Immune Chemical Liver Lung Blood Kidney cytotoxicity system system system system Potassium cyanide x x x (±)-Verapamil x hydrochloride 1-Phenyl-2-thiourea x x 1-Phenyl-3- x x pyrazolidone Barium chloride x x ax x Brucine x x x Chloral hydrate x x x x x cis- Diammineplatinum x x (II) dichloride D-Amphetamine x Dichlorvos x x x Disulfoton x Endosulfan x x Epinephrine x x hydrogen tartrate Fenpropathrin x Lindane x x x x Malononitrile x x ax x x x x x Mercury II chloride x bx x Methadone x x hydrochloride Nicotine x x Ochratoxin A x x x Paraquat dichloride x x x x Parathion ax x Pentachlorophenol x x x x Phenobarbital ax x ax physostigmine x Sodium pentobarbital ax x Sodium salt of x x x chloroacetic acid Strychnine x x Thallium sulphate x x x Theophylline x x x x Triethylenemelamine x x x Warfarin x x GI: Gastrointestinal; CLP: Classification, labelling and packaging; NRU: Neutral Red Uptake; a indirect effect; b corrosive ALTEX ##(#), SUPPLEMENTARY DATA 2 Tab. S3: Overview of collected information on specific target organ/system and general cytotoxicity for chemicals with CLP acute oral toxicity category over-predicted 3T3 NRU cytotoxicity assay Nervous Cardiovascular GI Immune Chemical Cytotoxicity Liver Lung Blood Kidney system system system system 17α- x x x Ethynyloestradiol 1-Naphthylamine x Amitriptilyne x x x hydrochloride Diquat Dibromide x x x x Haloperidol x x Maprotiline x x N-isopropyl-N'- phenyl-p- x phenylenediamine Tert-Butyl x x x hydroperoxide Triphenyltin x hydroxide GI: Gastrointestinal; CLP: Classification, labelling and packaging; NRU: Neutral Red Uptake Tab. S4: Specific target organ/systems and general cytotoxicity reported for the chemicals falsely predicted as negatives (i.e. LD50 > 2000 mg/kg) by the 3T3 NRU cytotoxicity assay General Nervous Cardiovascular GI Chemical Liver Lung Kidney cytotoxicity system system system Aconitine x x x Isoniazid x x x Diethylene glycol x x x Digoxin x Ethylene glycol x x x x Paraldehyde x x GI: Gastrointestinal; NRU: Neutral Red Uptake ALTEX ##(#), SUPPLEMENTARY DATA 3 Tab. S5: APOs outlined or fully developed with potential relevance to acute oral toxicity Adverse outcome MIE/Key Events Stressor References Cell death • Decompartmentalization Vinken and (Apoptosis/necrosis) • Direct mitochondrial inhibition Blaauboer, 1(AOP 205) • Narcosis 2017 In support of cytotoxicity as • Mitochondrial impairment (key event) general mechanism (non-cell specific) Haematotoxicity • Parent compound is converted to the 1(AOP 31) reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III) • Altered regulation of Alpha hemoglobin • Oxidative stress propagation • Damaging of Red blood cells; hemolysis • Formation of hemoglobin adducts • Down Regulation of Gulcose-6- phosphate dehydrogenase • Increase RBC congestion in liver • Increase Liver and splenic hemosiderosis • Decreased in hemoglobin, hematocrit, and red blood cell number (methaemoglobinemia) Acute liver response • PXR/SXR activation 1(AOP 11) • Key events unknown Cholestatic Liver Injury • Inhibition of Bile Salt Export Pump Vinken et al., 1(AOP 27) (ABCB11) 2013 • Activation of specific nuclear receptors, Transcriptional change • Bile accumulation • Cytokine Release • Increased Inflammation • Reactive oxygen species production • Peptide Oxidation Liver inflammation • Lysosome disruption • Iron compounds 1(AOP 144) • Peptide oxidation • ROS • Mitochondrial dysfunction 1 • o-methyl-serine • Cell injury/death dodecylamide • Cytokine Release hydrochloride (MSDH) • Inflammatory cells • alpha-tocopheryl succinate • 3-aminopropanal • artesunate • naphtharazine • Fluoroquinolones Decrease lung function • EGFR activation • ROS 1(AOP 148) • Trans differentiation of ciliated epithelial cells • Metaplasia of goblet cells • Goblet cell hyperplasia • Proliferation of goblet cells • SP1 Activation • Apoptosis of ciliated epithelial cells • Increased Mucin production • Chronic Mucus hypersecretion Increased mortality (Impaired • Impaired ion channels heart function) • Altered action potential 1(AOP 104) • Increased cardiac arrthymia Hypertension • Peptide Oxidation • ROS 1(AOP 149) • S-Glutathionylation, eNOS • Decrease in GTPCH-1 • Decrease in Tetrahydrobiopterin • Uncoupling of eNOS ALTEX ##(#), SUPPLEMENTARY DATA 4 Adverse outcome MIE/Key Events Stressor References • Depletion of Nitric Oxide • Impaired Vasodilation • Increase in Vascular Resistance • Decrease in AKT/eNOS activity Learning and impaired • Binding of agonist to ionotropic • Domoic acid memory glutamate receptors 4(AOP 48) • Mitochondrial dysfunction 1 • Cell injury/death • Neurodegeneration • Overactivation of NMDARs • Intracellular Calcium overload • Decreased in neuronal network function in adult brain • Neuroinflammation Epiletic seizures • Binding at picrotoxin site of iGABAR • Lindane 2(AOP 10) chloride channel • Endosulfan • Reduction in ionotropic GABA receptor • Picrotoxin chloride channel conductance • Dieldrin • Reduction of neuronal synaptic inhibition • Heptachlor • Generation of amplified excitatory • RDX postsynaptic potential (EPSP) • Fipronil • Occurrence of A paroxysmal depolarizing shift Parkinsonian motor deficits • Binding of inhibitor to NADH-ubiquinone • MPP+ 3(AOP 3) oxidoreductase (complex I) • Inhibition of NADH-ubiquinone oxidoreductase (complex I) • Mitochondrial dysfunction 1 • Impaired proteostasis • Neuroinflammation • Degeneration of dopaminergic neurons of the nigrostriatal pathway Acute mortality • Inhibition of acetylcholinesterase (AchE) • Organophosphates Russom et 1(AOP 16) • Accumulation of acetylcholine in • Carbamates al., 2014 synapses • Increased atrioventricular block and bradycardia • Increased respiratory distress/arrest • Induction of ataxia, paralysis, or hyperactivity Acute mortality • Modulation of sodium channel • Cypermethrin 1(AOP 96) • Prolonged depolarization of neuronal • Permethrin membrane • Esfenvalerate • Neuronotransmitter release • Tralomethrin • Muscle contraction • Bifenthrin • Increased ataxia, paralysis, or • Cyfluthrin hyperactivity • Lambda-Cyhalothrin Neurodegeneration • Binding to SH/seleno proteins • Mercuric chloride 1(AOP 17) • Oxidative Stress • Acrylamide • Glutamate dyshomeostasis • Acrolein • Cell injury/death • Methylmercuric(II) • Neuroinflammation chloride • Tissue resident cell activation • Thiomersal • Increased of pro-inflammatory mediators • Decrease of neuronal network function The acute neurotoxicity • Binding to the alpha subunit of voltage- • Pyrethroid Bal-Price et induced by binding of gated sodium channels. al., 2017 pyrethroid insecticides to • Changes in the kinetics of channel voltage-gated sodium opening and closing. channels • Alterations in excitability of neuronal membranes. • Dysregulation of neural networks (not in AOP-Wiki) Delayed neuropathy • Binding to neuropathy target esterase • Organophosphates Bal-Price et (NTE) al., 2015 Colony loss/failure • MIE unknown • Suppression of the immune system ALTEX ##(#), SUPPLEMENTARY DATA 5 Adverse outcome MIE/Key Events Stressor References 1(AOP 84) • Increased viral susceptibility • Impaired development Colony loss/failure • MIE unknown 1(AOP 85) • Suppression of the immune system • Increased viral susceptibility • Abnormal foraging activity and behavior Inhibition/activation of gastric • MIE unknown • Nonsteroidal anti- ulcer formation • Inhibition of
Recommended publications
  • National Center for Toxicological Research

    National Center for Toxicological Research

    National Center for Toxicological Research Annual Report Research Accomplishments and Plans FY 2015 – FY 2016 Page 0 of 193 Table of Contents Preface – William Slikker, Jr., Ph.D. ................................................................................... 3 NCTR Vision ......................................................................................................................... 7 NCTR Mission ...................................................................................................................... 7 NCTR Strategic Plan ............................................................................................................ 7 NCTR Organizational Structure .......................................................................................... 8 NCTR Location and Facilities .............................................................................................. 9 NCTR Advances Research Through Outreach and Collaboration ................................... 10 NCTR Global Outreach and Training Activities ............................................................... 12 Global Summit on Regulatory Science .................................................................................................12 Training Activities .................................................................................................................................14 NCTR Scientists – Leaders in the Research Community .................................................. 15 Science Advisory Board ...................................................................................................
  • A Screening-Based Approach to Circumvent Tumor Microenvironment

    A Screening-Based Approach to Circumvent Tumor Microenvironment

    JBXXXX10.1177/1087057113501081Journal of Biomolecular ScreeningSingh et al. 501081research-article2013 Original Research Journal of Biomolecular Screening 2014, Vol 19(1) 158 –167 A Screening-Based Approach to © 2013 Society for Laboratory Automation and Screening DOI: 10.1177/1087057113501081 Circumvent Tumor Microenvironment- jbx.sagepub.com Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia Harpreet Singh1,2, Anang A. Shelat3, Amandeep Singh4, Nidal Boulos1, Richard T. Williams1,2*, and R. Kiplin Guy2,3 Abstract Signaling by the BCR-ABL fusion kinase drives Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myelogenous leukemia (CML). Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL. While host-derived growth factors in the leukemia microenvironment have been invoked to explain this drug resistance, their relative contribution remains uncertain. Using genetically defined murine Ph+ ALL cells, we identified interleukin 7 (IL-7) as the dominant host factor that attenuates response to BCR-ABL-KIs. To identify potential combination drugs that could overcome this IL-7–dependent BCR-ABL-KI–resistant phenotype, we screened a small-molecule library including Food and Drug Administration–approved drugs. Among the validated hits, the well-tolerated antimalarial drug dihydroartemisinin (DHA) displayed potent activity in vitro and modest in vivo monotherapy activity against engineered murine BCR-ABL-KI–resistant Ph+ ALL. Strikingly, cotreatment with DHA and dasatinib in vivo strongly reduced primary leukemia burden and improved long-term survival in a murine model that faithfully captures the BCR-ABL-KI–resistant phenotype of human Ph+ ALL.
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC

    1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC

    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
  • WO 2014/185925 Al 20 November 2014 (20.11.2014) P O P C T

    WO 2014/185925 Al 20 November 2014 (20.11.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/185925 Al 20 November 2014 (20.11.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BOW 53/28 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/04 1503 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 17 May 2013 (17.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (71) Applicant: EMPIRE TECHNOLOGY DEVELOP¬ (84) Designated States (unless otherwise indicated, for every MENT LLC [US/US]; 271 1 Centerville Road, Suite 400, kind of regional protection available): ARIPO (BW, GH, Wilmington, Delaware 19808 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: PEPPOU, George Charles; 4 Armen Way, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Hornsby Heights, New South Wales 2077 (AU).
  • Avant-Propos Le Format De Présentation De Cette Thèse Correspond À Une Recommandation À La Spécialité

    Avant-Propos Le Format De Présentation De Cette Thèse Correspond À Une Recommandation À La Spécialité

    Avant-propos Le format de présentation de cette thèse correspond à une recommandation à la spécialité Maladies infectieuses, à l’intérieur du Master des Sciences de la Vie et de la Santé qui dépend de l’Ecole Doctorale des Sciences de la Vie de Marseille. Le candidat est amené à respecter les règles qui lui sont imposées et qui comportent un format de thèse utilisé dans le Nord de l’Europe et qui permet un meilleur rangement que les thèses traditionnelles. Par ailleurs, la partie introduction et bibliographie est remplacée par une revue envoyée dans un journal afin de permettre une évaluation extérieure de la qualité de la revue et de permettre à l’étudiant de commencer le plus tôt possible une bibliographie sur le domaine de cette thèse. Par ailleurs, la thèse est présentée sur article publié, accepté, ou soumis associé d’un bref commentaire donnant le sens général du travail. Cette forme de présentation a paru plus en adéquation avec les exigences de la compétition internationale et permet de se concentrer sur des travaux qui bénéficieront d’une diffusion internationale. Professeur Didier RAOULT 2 Remerciements J’adresse mes remerciements aux personnes qui ont contribué à la réalisation de ce travail. En premier lieu, au Professeur Didier RALOUT, qui m’a accueillie au sein de l’IHU Méditerranée Infection. Au Professeur Serge MORAND, au Docteur Marie KEMPF et au Professeur Philippe COLSON de m’avoir honorée en acceptant d’être rapporteurs et examinateurs de cette thèse. Je souhaite particulièrement remercier : Le Professeur Jean-Marc ROLAIN, de m’avoir accueillie dans son équipe et m’avoir orientée et soutenue tout au long de ces trois années de thèse.
  • Step-By-Step Guide to Better Laboratory Management Practices

    Step-By-Step Guide to Better Laboratory Management Practices

    Step-by-Step Guide to Better Laboratory Management Practices Prepared by The Washington State Department of Ecology Hazardous Waste and Toxics Reduction Program Publication No. 97- 431 Revised January 2003 Printed on recycled paper For additional copies of this document, contact: Department of Ecology Publications Distribution Center PO Box 47600 Olympia, WA 98504-7600 (360) 407-7472 or 1 (800) 633-7585 or contact your regional office: Department of Ecology’s Regional Offices (425) 649-7000 (509) 575-2490 (509) 329-3400 (360) 407-6300 The Department of Ecology is an equal opportunity agency and does not discriminate on the basis of race, creed, color, disability, age, religion, national origin, sex, marital status, disabled veteran’s status, Vietnam Era veteran’s status or sexual orientation. If you have special accommodation needs, or require this document in an alternate format, contact the Hazardous Waste and Toxics Reduction Program at (360)407-6700 (voice) or 711 or (800) 833-6388 (TTY). Table of Contents Introduction ....................................................................................................................................iii Section 1 Laboratory Hazardous Waste Management ...........................................................1 Designating Dangerous Waste................................................................................................1 Counting Wastes .......................................................................................................................8 Treatment by Generator...........................................................................................................12
  • Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit

    Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit

    Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit: Impact on Central Line–Associated Bloodstream Infections Author(s): Caroline Quach, MD, MSc; Aaron M. Milstone, MD, MHS; Chantal Perpête, RN, LSH, LSHH; Mario Bonenfant, RN; Dorothy L. Moore, MD, PhD; Therese Perreault, MD Source: Infection Control and Hospital Epidemiology, Vol. 35, No. 2 (February 2014), pp. 158- 163 Published by: The University of Chicago Press on behalf of The Society for Healthcare Epidemiology of America Stable URL: http://www.jstor.org/stable/10.1086/674862 . Accessed: 24/01/2014 14:25 Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at . http://www.jstor.org/page/info/about/policies/terms.jsp . JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact [email protected]. The University of Chicago Press and The Society for Healthcare Epidemiology of America are collaborating with JSTOR to digitize, preserve and extend access to Infection Control and Hospital Epidemiology. http://www.jstor.org This content downloaded from 209.172.182.131 on Fri, 24 Jan 2014 14:25:10 PM All use subject to JSTOR Terms and Conditions infection control and hospital epidemiology february 2014, vol. 35, no. 2 original article Chlorhexidine Bathing in a Tertiary Care Neonatal Intensive Care Unit: Impact on Central Line–Associated Bloodstream Infections Caroline Quach, MD, MSc;1,2,3 Aaron M.
  • Chemicals of High Concern List (Sorted Alphabetically), July 2010

    Chemicals of High Concern List (Sorted Alphabetically), July 2010

    Minnesota Department of Health, Chemicals of High Concern list, July 1, 2010 Persistent, Bioaccumulative, Toxic or very CAS Persistent, very HPV (2006 and 3 of 4 Number Chemical Name Health endpoint(s) Bioaccumulative Source(s) Use example(s) or class years) (S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2- Maine (EU Reproductive 5543-57-7 benzopyrone Reproduction Toxicant) Sunscreen Maine (CA Prop 65; IARC; EU Carcinogen; NTP 11th ROC; OSPAR Chemicals of High Concern); WA Appen1; 91-94-1 [1,1'-biphenyl]-4,4'-diamine, 3,3'-dichloro-Cancer x Minnesota HRL Dye, curing agent Maine (OSPAR Chemicals of [1,1'-biphenyl]-4,4'-diamine, N,N'-bis(2,4- Concern; Canada PBiT); WA 29398-96-7 dinitrophenyl)-3,3'-dimethoxy- x Appen1 Colorant [1,1'-Biphenyl]-4-ol, 3,4',5-tris(1,1- Maine (Canada PBiT); WA 6257-39-2 dimethylethyl)- x Appen1 [1,1'-Biphenyl]-4-ol, 3,4'-bis(1,1- Maine (Canada PBiT); WA 42479-88-9 dimethylethyl)- x Appen1 Chemical intermediate [1,1'-biphenyl]-4-ol, 3,5-bis(1,1- Maine (OSPAR Chemicals of 2668-47-5 dimethylethyl)- x Concern); WA Appen1 [2,6'-Bibenzothiazole]-7-sulfonic acid, 2'- (4-aminophenyl)-6-methyl-, diazotized, coupled with diazotized 4- aminobenzenesulfonic acid and Maine (Canada PBiT); WA 91696-90-1 resorcinol, sodium salts x Appen1 1(2H)-Quinolineethanol, 6-[(2-chloro-4,6- dinitrophenyl) azo]-3,4-dihydro-2,2,4,7- Maine (Canada PBiT); WA 63133-84-6 tetramethyl- x Appen1 1(2H)-Quinolinepropanamide, 6-(2,2- dicyanoethenyl)-3, 4-dihydro-2,2,4,7- Maine (Canada PBiT); WA 63467-15-2 tetramethyl-N-phenyl- x Appen1 1,1,1,2-Tetrachloro-2,2-bis(4-
  • Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008

    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008

    Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 William A. Rutala, Ph.D., M.P.H.1,2, David J. Weber, M.D., M.P.H.1,2, and the Healthcare Infection Control Practices Advisory Committee (HICPAC)3 1Hospital Epidemiology University of North Carolina Health Care System Chapel Hill, NC 27514 2Division of Infectious Diseases University of North Carolina School of Medicine Chapel Hill, NC 27599-7030 1 Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008 3HICPAC Members Robert A. Weinstein, MD (Chair) Cook County Hospital Chicago, IL Jane D. Siegel, MD (Co-Chair) University of Texas Southwestern Medical Center Dallas, TX Michele L. Pearson, MD (Executive Secretary) Centers for Disease Control and Prevention Atlanta, GA Raymond Y.W. Chinn, MD Sharp Memorial Hospital San Diego, CA Alfred DeMaria, Jr, MD Massachusetts Department of Public Health Jamaica Plain, MA James T. Lee, MD, PhD University of Minnesota Minneapolis, MN William A. Rutala, PhD, MPH University of North Carolina Health Care System Chapel Hill, NC William E. Scheckler, MD University of Wisconsin Madison, WI Beth H. Stover, RN Kosair Children’s Hospital Louisville, KY Marjorie A. Underwood, RN, BSN CIC Mt. Diablo Medical Center Concord, CA This guideline discusses use of products by healthcare personnel in healthcare settings such as hospitals, ambulatory care and home care; the recommendations are not intended for consumer use of the products discussed. 2
  • Sodium Cyanate Manufaturer… TIRUPATI CYANATE

    Sodium Cyanate Manufaturer… TIRUPATI CYANATE

    Sodium Cyanate Manufaturer… TIRUPATI CYANATE www.tirupaticyanate.com ABOUT US___________________________________________________ Tirupati cyanate is leading manufacturer and provider of sodium cyanate. Our excellent customer service and high quality of Sodium cyanate in bulk makes us unique in the market. Tirupati cyanate is exporters of sodium cyanate in volumes to supply to the demands of its customers in local market and around the world. We undertake custom synthesis and manufacture sodium cyanate as per demand and under secrecy agreement. Please enquire and contact us for further information on sodium cynate mentioning your specific requirements. Sodium Cyanate Specification CAS No 917-61-3 Cyanic Acid, Sodium Salt, Natriumcyanat 9, Synonym Cianato de sodio, Cyanate de sodium Molecular Weight 65.01 Empirical Formula NaOCn Sodium Cyanate Physical property Purity Minimum 90% Melting Point 550°C Density 1.893 g/cm3 Solubility 10 gm at 25ºC Physical Appearance Free Flowing White Powder Soda Ash Content Less Than 5% Cyanate (-OCN) Content Between 59.5 % to 61.3 % Loss on Drying (At 110ºC)Max Maximum 0.05 Packaging Information HDPE Bags inside liner of 25kgs, 50 Kgs. Capacity Company Tirupati cyanate, chhatral GIDC industrial estate, Dist. Gandhinagar, Gujarat, India Sodium cyanate Application Sodium Cyanate is mainly used as herbicides & in heat treatment of metal. As herbicides it is used mostly to wipeout weeds in lawns and onion crops. It also used as a fertilizer because sodium cyanate contains high volume of nitrogen. Copyright © TIRUPATI CYANATE 2005-2013 Sodium Cyanate Manufaturer… TIRUPATI CYANATE www.tirupaticyanate.com Sodium cyanate is also used in the synthesis of pesticides and dyes intermediates.
  • 2019 Minnesota Chemicals of High Concern List

    2019 Minnesota Chemicals of High Concern List

    Minnesota Department of Health, Chemicals of High Concern List, 2019 Persistent, Bioaccumulative, Toxic (PBT) or very Persistent, very High Production CAS Bioaccumulative Use Example(s) and/or Volume (HPV) Number Chemical Name Health Endpoint(s) (vPvB) Source(s) Chemical Class Chemical1 Maine (CA Prop 65; IARC; IRIS; NTP Wood and textiles finishes, Cancer, Respiratory 11th ROC); WA Appen1; WA CHCC; disinfection, tissue 50-00-0 Formaldehyde x system, Eye irritant Minnesota HRV; Minnesota RAA preservative Gastrointestinal Minnesota HRL Contaminant 50-00-0 Formaldehyde (in water) system EU Category 1 Endocrine disruptor pesticide 50-29-3 DDT, technical, p,p'DDT Endocrine system Maine (CA Prop 65; IARC; IRIS; NTP PAH (chem-class) 11th ROC; OSPAR Chemicals of Concern; EuC Endocrine Disruptor Cancer, Endocrine Priority List; EPA Final PBT Rule for 50-32-8 Benzo(a)pyrene x x system TRI; EPA Priority PBT); Oregon P3 List; WA Appen1; Minnesota HRV WA Appen1; Minnesota HRL Dyes and diaminophenol mfg, wood preservation, 51-28-5 2,4-Dinitrophenol Eyes pesticide, pharmaceutical Maine (CA Prop 65; IARC; NTP 11th Preparation of amino resins, 51-79-6 Urethane (Ethyl carbamate) Cancer, Development ROC); WA Appen1 solubilizer, chemical intermediate Maine (CA Prop 65; IARC; IRIS; NTP Research; PAH (chem-class) 11th ROC; EPA Final PBT Rule for 53-70-3 Dibenzo(a,h)anthracene Cancer x TRI; WA PBT List; OSPAR Chemicals of Concern); WA Appen1; Oregon P3 List Maine (CA Prop 65; NTP 11th ROC); Research 53-96-3 2-Acetylaminofluorene Cancer WA Appen1 Maine (CA Prop 65; IARC; IRIS; NTP Lubricant, antioxidant, 55-18-5 N-Nitrosodiethylamine Cancer 11th ROC); WA Appen1 plastics stabilizer Maine (CA Prop 65; IRIS; NTP 11th Pesticide (EPA reg.
  • June 16, 2014 Colleen Rogers Center for Drug Evaluation and Research

    June 16, 2014 Colleen Rogers Center for Drug Evaluation and Research

    June 16, 2014 Colleen Rogers Center for Drug Evaluation and Research Food and Drug Administration Building 22, Room 5411 10903 New Hampshire Avenue Silver Spring, MD 20993 Re: Proposed Rule: Proposed Amendment of the Tentative Final Monograph, Federal Register, Vol. 78, No. 242, Tuesday, December 17, 2013. Docket identification (ID) number: FDA-1975-N-0012 Regulatory Information Number: 0910-AF69 Dear Ms. Rogers: The American Cleaning Institute (ACI)1 appreciates this opportunity to provide comments on the proposed rule to amend the 1994 tentative final monograph (the 1994 TFM) for over-the-counter (OTC) antiseptic drug products to establish conditions under which OTC consumer antiseptic products intended for use with water (referred to throughout as consumer antiseptic washes) are generally recognized as safe and effective. ACI has a specific interest in triclosan (TCS) within the proposed rule since our members produce consumer antiseptic wash products containing triclosan and manufacture triclosan. Triclosan-containing consumer antiseptic wash products play a beneficial role in the daily hygiene routines of millions of people throughout the U.S. and worldwide. They have been and are used safely and effectively in homes, hospitals, schools and workplaces every single day. Furthermore, triclosan and products containing it are regulated by a number of governmental bodies around the world and have a long track record of human and environmental safety which is supported by a multitude of science-based, transparent risk analyses. ACI members are concerned that FDA has not appropriately assessed the safety data that are available prior to proposing that additional safety data are necessary to support the safety of triclosan for this use.